| (Values in U.S. Thousands) | Feb, 2023 | Aug, 2022 | May, 2022 | Feb, 2022 | Aug, 2021 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | +100.00% |
| Net Income | 219 | -179 | -74 | -900 | -882 |
| Net Income Growth | +222.45% | -141.16% | +91.77% | -2.11% | -35.60% |
Neonmind Biosciences Inc (NEON.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
NeonMind Biosciences Inc is engaged in drug development research into potential therapeutic uses of psychedelic compounds. The company operates two divisions: a pharmaceutical division engaged in drug development of psychedelic compounds with two psilocybin-based drug candidates targeting obesity; a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.